Share on StockTwits

Cytori Therapeutics (NASDAQ:CYTX) Director David Rickey bought 30,000 shares of the stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average cost of $2.34 per share, with a total value of $70,200.00. Following the transaction, the director now directly owns 15,819 shares of the company’s stock, valued at approximately $37,016. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Maxim Group cut their price target on shares of Cytori Therapeutics from $10.00 to $9.00 in a research note on Tuesday, May 13th. They now have a “buy” rating on the stock.

Cytori Therapeutics (NASDAQ:CYTX) traded up 2.59% during mid-day trading on Monday, hitting $2.38. The stock had a trading volume of 400,363 shares. Cytori Therapeutics has a one year low of $2.00 and a one year high of $3.93. The stock has a 50-day moving average of $2.34 and a 200-day moving average of $2.63. The company’s market cap is $179.6 million.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.14) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.14). The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $2.87 million. Analysts expect that Cytori Therapeutics will post $-0.40 EPS for the current fiscal year.

Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.